iPS Cell Screening for Alzheimer's Aβ Oligomer Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing and treating Alzheimer's disease are inadequate for early detection and radical treatment, as existing diagnostic criteria fail to accurately identify the disease at its onset, and available therapeutic agents only delay disease progression.
Innovation Solution
A method involving induced pluripotent stem cells (iPS cells) derived from patients with Alzheimer's disease is used to recreate the diseased state in nerve cells or astrocytes, allowing for the screening of therapeutic and prophylactic agents by measuring Aβ oligomer accumulation and associated stress indices before and after exposure to candidate substances.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional diagnostic criteria (NINCDS-ADRDA and DSM-IV) are used, then dementia diagnosis can be made, but early stage diagnosis accuracy deteriorates
Solution Approach 1:
The patent uses iPS cells derived from patient somatic cells to recreate the diseased state before clinical symptoms appear. By inducing differentiation into nerve cells and measuring Aβ oligomers and stress indices in advance, the method enables early detection at the pre-symptomatic stage, resolving the contradiction between early detection timing and diagnostic accuracy.
2Duration of action of moving object
If existing therapeutic agents (e.g., Aricept) are used, then disease progression can be delayed, but radical treatment effect deteriorates
Solution Approach 1:
The screening method identifies compounds that prevent Aβ oligomer formation and reduce stress indices before nerve cell death occurs. By detecting therapeutic candidates at the pre-symptomatic stage using iPS cell-derived nerve cells, the method enables radical treatment that addresses the root cause rather than merely delaying progression.
Solution Approach 2:
The patent creates in vitro copies of patient-specific nerve cells using iPS cell technology. These copied cells reproduce the exact diseased state with Aβ accumulation and stress responses, allowing high-throughput screening of therapeutic candidates without risking patient safety while maintaining disease-specific accuracy.
3Measurement precision
If iPS cells are used to recreate diseased state, then early diagnosis capability improves, but device complexity deteriorates
Solution Approach 1:
The patent segments the complex disease diagnosis into distinct measurable parameters: Aβ oligomer levels, ER stress indices (BiP, CHOP), and oxidative stress markers. This segmentation allows each parameter to be measured independently using established assays, simplifying the overall screening system while maintaining high early detection accuracy.
Data Source
Figure 1A~1F
Figure 2A~2C
Figure 3A~3B
AI summary
The present invention provides a method for screening a therapeutic and/or prophylactic agent for Alzheimer's disease using at least one index selected from the group consisting of the levels of Aβ oligomers, BiP, cleaved caspase 4, PRDX4 and ROS in nerve cells or the like whose differentiation has been induced from iPS cells derived from somatic cells of a patient with Alzheimer's disease.